Stocks Health care NNNN
NASDAQ · Health careAnbio Biotechnology (NNNN)
Anbio Biotechnology reported revenue of $8.6M in fiscal 2025, up 5.6% from a year earlier. Net income was $6.4M, a net margin of 74.1%. At December 31, 2025 it held $7.8M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on April 9, 2026.
Key facts about Anbio Biotechnology
- Net worth
- Anbio Biotechnology has a market value (market cap) of $587.1M at the latest share price, and shareholders' equity of $30.2M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $8.6M (+5.6% year on year), with net income of $6.4M.
- Cash flow
- In fiscal 2025 operations used $6.7M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer, amended), 20-F/A) was filed with the SEC on April 9, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Anbio Biotechnology does
Anbio Biotechnology is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker NNNN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $8.6M | $6.4M | $0.15 | n/a |
| 2024 | $8.2M | $2.4M | $0.06 | n/a |
| 2024 | $6.7M | $2.3M | $0.11 | n/a |
| 2022 | $23.5M | $10M | $100,112.00 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NNNN ranks in Health care
Latest SEC filings
What Anbio Biotechnology has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 9, 2026Form F-3ASR filing F-3ASR
- May 19, 2026
- April 27, 2026
- April 9, 2026Annual report (foreign issuer, amended) 20-F/A · period to December 31, 2025Revenue rose 5.6% to $8.6M versus the prior year; diluted EPS $0.15 versus $0.06.
- April 7, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue rose 5.6% to $8.6M versus the prior year; diluted EPS $0.15 versus $0.06.
- February 17, 2026
- January 26, 2026
- December 30, 2025
- November 13, 2025
- April 28, 2025Annual report (foreign issuer) 20-F · period to December 31, 2024Revenue rose 22% to $8.2M versus the prior year; diluted EPS $0.06 versus $0.11.
Insider trades
What the people running Anbio Biotechnology did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about NNNN
What does Anbio Biotechnology do?
Anbio Biotechnology is a company in the Health care sector, listed on NASDAQ as NNNN. Its shares trade on NASDAQ under the ticker NNNN.
What is Anbio Biotechnology's net worth?
Anbio Biotechnology has a market value (market cap) of $587.1M at the latest share price, and shareholders' equity of $30.2M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Anbio Biotechnology profitable?
Yes. In fiscal 2025 it reported net income of $6.4M on revenue of $8.6M, a net margin of 74.1%.
How much revenue does Anbio Biotechnology make?
In fiscal 2025 Anbio Biotechnology reported revenue of $8.6M. That is 5.6% more than a year earlier.
When did Anbio Biotechnology last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on April 9, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the form F-3ASR filing from July 9, 2026.
Similar companies
Compare NNNN with
Follow NNNN
Get an email when Anbio Biotechnology files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Anbio Biotechnology tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.